Dana-Farber Cancer Institute

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Dana-Farber Cancer Institute sits in the top decile of US sponsors by registered trial count (#42 of 15,742 sponsors by registered trial count).

781 total trials 112 currently recruiting 449 completed early-phase tilt top decile by trial count

Dana-Farber Cancer Institute: 781 sponsored US clinical trials, 112 recruiting.

Dana-Farber Cancer Institute sponsors 781 registered US clinical trials on ClinicalTrials.gov, 112 of them currently recruiting, and 449 completed. 15 of these trials are in Phase 3-4 (later-stage) and 492 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 53 trials.

Top-decile sponsor footprint

Dana-Farber Cancer Institute ranks in the top decile of sponsors by registered trial count (#42 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 49/100

449 of 537 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

781 total, page 6 of 16

COMPLETED NA

Development and Piloting an Avatar-based Intervention to Support Patients Undergoing Stem Cell Transplantation

NCT05600101
COMPLETED

The SPOT-HPV Study

NCT05524025
COMPLETED NA

Sleep Treatment Education Program for Young Adult Cancer Survivors (STEP-YA)

NCT05358951
COMPLETED NA

Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial)

NCT05528263
COMPLETED NA

STAMP+CBT mHealth for Cancer Pain

NCT05403801
COMPLETED NA

Early Interventional Treatment for Cancer Pain

NCT05366413
COMPLETED Phase 1

ASP8374 + Cemiplimab in Recurrent Glioma

NCT04826393
TERMINATED NA

Axillary Lymph Node Tattoo Marking Study

NCT04947917
COMPLETED NA

Move Together Boston Feasibility Pilot (Sit Less, Move More App for Black Breast Cancer Survivors & At-Risk Relatives)

NCT05011279
COMPLETED NA

TIPOPS (Telemedicine vs In Person Oncology Patient Surveillance)

NCT04936243
COMPLETED Phase 1

Intravenous Magnesium in Patients Receiving Cisplatin

NCT04481672
COMPLETED

Feasibility Pilot Exploring Variability in Biomarkers and PROs in AML

NCT04908852
COMPLETED NA

My Mindful Moments: A Mindfulness Meditation and Digital Art Activity

NCT04557033
TERMINATED Phase 2

Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

NCT04899921
COMPLETED NA

Survivor-Sleep Health Information Program

NCT04863157
COMPLETED NA

Routine Evaluation of the Social Determinants of Health in Oncology: User-centered Resource Coordination and Engagement

NCT04879927
COMPLETED NA

AWARENESS Trial (AWARENESS) of Storytelling Through Music in Healthcare Workers

NCT04775524
COMPLETED NA

Step Into Support for Endurance and Strength (SISTERS)

NCT04354454
COMPLETED NA

Feasibility of Fasting & Exercise in Pts With HR+ MBC

NCT04708860
COMPLETED Phase 1

ABEMA Alone or in COMBO With MK-6482

NCT04627064
COMPLETED Phase 1

Cabozantinib With Topotecan-Cyclophosphamide

NCT04661852
COMPLETED

Advance Care Planning: Communicating With Outpatients for Vital Informed Decision

NCT04660422
COMPLETED NA

REVITALIZE: A Telehealth Intervention for Women With Advanced Ovarian Cancer and PARP Inhibitor-Related Fatigue

NCT04525183
COMPLETED NA

RESIST-ADT (Androgen Deprivation Therapy)

NCT04485767
COMPLETED NA

Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers

NCT04330716
COMPLETED Phase 1

Effect of Perampanel on Peritumoral Hyperexcitability in HGG

NCT04497142
COMPLETED Phase 1

Cemiplimab in AlloSCT/SOT Recipients With CSCC

NCT04339062
COMPLETED Phase 2

Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy

NCT04479514
TERMINATED Phase 1

Phase I Study of Marizomib + Panobinostat for Children With DIPG

NCT04341311
TERMINATED Phase 2

VB-111 in Surgically Accessible Recurrent/Progressive GBM

NCT04406272
COMPLETED Phase 1

CIML NK Cell in Head & Neck Cancer

NCT04290546
COMPLETED Phase 1

LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy

NCT04081259
TERMINATED Phase 3

Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT

NCT03777982
COMPLETED NA

Advance Care Planning: Promoting Effective and Aligned Communication in the Elderly

NCT03609177
TERMINATED Phase 1

GVAX Plus Checkpoint Blockade in Neuroblastoma

NCT04239040
TERMINATED Phase 2

Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies

NCT03717480
TERMINATED Phase 2

Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions

NCT04071756
COMPLETED Phase 2

Cabozantinib and Nivolumab for Carcinoid Tumors

NCT04197310
COMPLETED NA

OPTimizing Treatment Focused Genetic Testing IN Cancer

NCT04066361
COMPLETED NA

Videos for Advance Care Planning in Young Adults

NCT04149704
TERMINATED Phase 2

Palbociclib + Ganitumab In Ewing Sarcoma

NCT04129151
COMPLETED NA

Smart Phone App Intervention In Young Adults With Cancer

NCT04119869
COMPLETED Phase 1

Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer

NCT03936465
TERMINATED NA

The Value of Advanced MR Imaging in Gynecological Tumors and Benign Uterine Fibroids

NCT03993210
COMPLETED NA

Yoga for Painful Chemotherapy-Induced Peripheral Neuropathy: A Pilot, Randomized-Controlled Study

NCT03824860
COMPLETED Phase 2

A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma

NCT03999684
COMPLETED NA

Symptom Management Implementation of Patient Reported Outcomes in Oncology

NCT03850912
COMPLETED NA

Mobile Health App to Mitigate the Metabolic Effects of Androgen Deprivation Therapy

NCT03761160
COMPLETED Phase 2

Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer

NCT03894891
COMPLETED Phase 2

A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas

NCT03899805
← Previous Page 6 of 16 Next →

Phase Distribution

PhaseTrial count
Phase 1 181
Phase 2 311
Phase 3 14
Phase 4 1

Therapeutic Areas

Breast Cancer 53
Prostate Cancer 21
Leukemia 13
Ovarian Cancer 13
Lung Cancer 11
Pancreatic Cancer 9
Myelodysplastic Syndromes 9
Multiple Myeloma 8
Head and Neck Cancer 8
Cancer 8

What is open in the Dana-Farber Cancer Institute pipeline

112 recruiting of 781 indexed (14% open); 449 completed (57%).

Phase mix: 15 late (III/IV) vs 492 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (53 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Dana-Farber Cancer Institute: open-pipeline peers nationwide

Peers matched on 781 registered trials and 14% open enrollment, not the therapeutic-area sidebar.

Dana-Farber Cancer Institute sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 02004006008001,000 14%16%18%20%22% Total trials Recruiting share Dana-Farber Cancer InstituteUniversity of California, San DiegoUniversity of ChicagoMedical University of South CarolinaUniversity of UtahThe Cleveland ClinicAcademic and Community Cancer Research UnitedAdaptive BiotechnologiesAgelessRx
Dana-Farber Cancer Institute sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Dana-Farber Cancer Institute sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 781 trials (± recruiting share)

Sponsors near 14% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Dana-Farber Cancer Institute page

781 registered trials is a research-attention snapshot, not an endorsement of Dana-Farber Cancer Institute or any single study.

  • 112 of Dana-Farber Cancer Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition Dana-Farber Cancer Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Dana-Farber Cancer Institute pipeline card: 781 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.